Publications

Explore a selection of our publications to date below.

ImageTitleYearjournal_hfilterpaper_type_hfilterfocus_hfiltertest_hfiltertumor_type_hfilterbiomarker_hfilterpublication_year_hfilter
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay2019oncotragetmanuscriptanalyticalmsisolid-tumorsanalytical-validation2019
Unique Tumor Immune Microenvironments Of Potentially PD-L1/TGF-β Trap Responsive Tumors
Unique Tumor Immune Microenvironments Of Potentially PD-L1/TGF-β Trap Responsive Tumors2019sitcs-34th-annual-meeting-2019abstractclinicalircsolid-tumorsbispecifics tumor-immune-microenvironment2019
CT Antigens are Frequently Expressed in Non-Inflamed Tumors
CT Antigens are Frequently Expressed in Non-Inflamed Tumors2019sitcs-34th-annual-meeting-2019abstractclinicalircsolid-tumorsct-antgiens tumor-immune-microenvironment2019
Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing
Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing2019journal-of-immunotherapy-and-precision-oncologymanuscriptanalyticaltcrbperipheral-blood-leukocyteshaplotype-analysis2019
Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC
Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC2019journal-of-thoracic-oncologymanuscriptclinicaloirrasolid-tumorsbmi immune-profile metformin2019
Oncologist uptake of comprehensive genomic profile guided targeted therapy
Oncologist uptake of comprehensive genomic profile guided targeted therapy2019oncotragetmanuscriptclinicalocpsolid-tumorsclinical-decision-making clinical-utility2019
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma2019asco-sitc-clinical-immuno-oncology-symposium-2019abstractclinicalircrenal-cell-carcinomacell-proliferation patient-response tumor-inflammation2019
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma (RCC)
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma (RCC)2019asco-sitc-clinical-immuno-oncology-symposium-2019abstractclinicalircrenal-cell-carcinomacell-proliferation patient-response tumor-inflammation2019
Tumor Mutational Burden (TMB): Assessment of Inter-and Intra-tumor heterogeneity
Tumor Mutational Burden (TMB): Assessment of Inter-and Intra-tumor heterogeneity2019asco-sitc-clinical-immuno-oncology-symposium-2019abstractanalyticaltmbsolid-tumorscomparator-study specimen-characteristics validation2019
RNA-sequencing reveals immunotherapy targets in gynecological cancer
RNA-sequencing reveals immunotherapy targets in gynecological cancer2019asco-sitc-clinical-immuno-oncology-symposium-2019abstractclinicalircgynocological-cancersimmune-profile immune-suppression2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients2019journal-for-immunotherapy-of-cancermanuscriptclinicalircnon-small-cell-lung-cancercell-proliferation patient-survival2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors2019journal-for-immunotherapy-of-cancermanuscriptanalyticalpd-l1-ihc pd-l1-rna-seqsolid-tumorscomparator-study patient-response pd-l12019
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing2019bmc-medical-informatics-and-decision-makingmanuscriptclinicalocpsolid-tumorsclinical-decision-making clinical-utility2019
RNA-Expression Profiling Reveals Immunotherapy Targets in Sarcoma
RNA-Expression Profiling Reveals Immunotherapy Targets in Sarcoma2018journal-of-sarcoma-researchmanuscriptclinicalircsarcomaimmune-profile myeloid-suppression2018
Identification of targets for prostate cancer immunotherapy
Identification of targets for prostate cancer immunotherapy2018the-prostatemanuscriptclinicalircprostate-cancerimmune-profile2018
Tumor mutational burden (TMB) ring study:  Comparison of multiple targeted next-generation sequencing (NGS) platforms
Tumor mutational burden (TMB) ring study: Comparison of multiple targeted next-generation sequencing (NGS) platforms2018asco-sitc-clinical-immuno-oncology-symposium-2018abstractanalyticaltmbsolid-tumorscomparator-study tmb2018
Identifying major immune subsets of GI tumors for clinical purposes
Identifying major immune subsets of GI tumors for clinical purposes2018sitcs-33rd-annual-meeting-2018abstractclinicalircgi-tumorsimmune-profile2018
Development of a next-generation sequencing-based microsatellite instability assay (MSI NGS) for solid tumor testing
Development of a next-generation sequencing-based microsatellite instability assay (MSI NGS) for solid tumor testing2018sitcs-33rd-annual-meeting-2018abstractanalyticalmsisolid-tumorsanalytical-validation2018
Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-Small Cell Lung Cancer
Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-Small Cell Lung Cancer2018asco-sitc-clinical-immuno-oncology-symposium-2018abstractclinicalpd-l1-22c3non-small-cell-lung-cancercell-proliferation patient-survival2018
Combination immunotherapy selection for non-PD-1 axis driven tumors
Combination immunotherapy selection for non-PD-1 axis driven tumors20182018-asco-annual-meetingabstractclinicaloirrasolid-tumorsimmune-profile2018
Combination immunotherapy selection for PD-1 axis driven tumors
Combination immunotherapy selection for PD-1 axis driven tumors20182018-asco-annual-meetingabstractclinicaloirrasolid-tumorsimmune-profile2018
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab2018oncoimmunologymanuscriptclinicalircurothelial-carcinomaimmune-profile patient-response pd-l22018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden2018journal-for-immunotherapy-of-cancermanuscriptclinicalircmelanomapatient-survival tumor-inflammation2018
Chemokine expression signatures in infiltrated vs non-infiltrated tumors
Chemokine expression signatures in infiltrated vs non-infiltrated tumors2018aacr-annual-meeting-2018abstractclinicalircsolid-tumorschemokines infiltrated-tumors tumor-infiltrating-lymphocytes2018
PD-L1 driven excluded phenotype in melanoma
PD-L1 driven excluded phenotype in melanoma2018aacr-annual-meeting-2018abstractclinicalircmelanomacd8 excluded-phenotype2018
Predicting Response: PD-L1 Biomarker Testing by IHC and RNA-seq
Predicting Response: PD-L1 Biomarker Testing by IHC and RNA-seq2018aacr-annual-meeting-2018abstractanalyticalircsolid-tumorspatient-response pd-l12018
Immune Deserts: Low CD8 Gene Expression Correlates with Non-response to Checkpoint Inhibition
Immune Deserts: Low CD8 Gene Expression Correlates with Non-response to Checkpoint Inhibition2018asco-sitc-clinical-immuno-oncology-symposium-2018abstractclinicalircsolid-tumorscd8 patient-response2018
Comprehensive Immune and Mutational Profile of Melanoma
Comprehensive Immune and Mutational Profile of Melanoma2018asco-sitc-clinical-immuno-oncology-symposium-2018abstractclinicaloamelanomaimmune-profile mutational-profile2018
CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in Melanoma
CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in Melanoma2018asco-sitc-clinical-immuno-oncology-symposium-2018abstractclinicaloamelanomactla4 patient-response2018
Lung Cancer Mutational Profile Correlates with Immune Profile
Lung Cancer Mutational Profile Correlates with Immune Profile2018asco-sitc-clinical-immuno-oncology-symposium-2018abstractclinicalirclung-cancerimmune-profile mutational-profile2018
Overexpression of Immunotherapeutic Targets in the Immune Desert Phenotype
Overexpression of Immunotherapeutic Targets in the Immune Desert Phenotype2017sitcs-32nd-annual-meeting-2017abstractclinicalircsolid-tumorsimmune-desert immune-profile2017
Comprehensive Characterization of Solid Tumor Immune Profiles for Precision Immunotherapy Using Immune Report Card℠
Comprehensive Characterization of Solid Tumor Immune Profiles for Precision Immunotherapy Using Immune Report Card℠2017sitcs-32nd-annual-meeting-2017abstractclinicalircsolid-tumorsimmune-profile2017
The Immune-Excluded Phenotype Beyond Colorectal Cancer
The Immune-Excluded Phenotype Beyond Colorectal Cancer2017sitcs-32nd-annual-meeting-2017abstractclinicalircsolid-tumorscd8 excluded-phenotype2017
Secondary Immunotherapeutic Targets In Inflamed Tumors
Secondary Immunotherapeutic Targets In Inflamed Tumors2017sitcs-32nd-annual-meeting-2017abstractclinicalircsolid-tumorsimmune-profile tumor-inflammation2017
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors2017the-journal-of-molecular-diagnosticsmanuscriptanalyticalircsolid-tumorsanalytical-validation2017
Algorithmic Prediction of Response to Checkpoint Inhibitors
Algorithmic Prediction of Response to Checkpoint Inhibitors20172017-asco-annual-meetingabstractanalyticaloirrasolid-tumorspatient-response predicitve-algorithm2017
The Inflamed Phenotype in PD-L1 Negative Melanoma and Response to Checkpoint Inhibitors
The Inflamed Phenotype in PD-L1 Negative Melanoma and Response to Checkpoint Inhibitors2017immunology-2017abstractclinicalircmelanomapatient-response tumor-inflammation2017
The Inflamed Phenotype in PD-L1 Negative NSCLC and Response to Checkpoint Inhibitors
The Inflamed Phenotype in PD-L1 Negative NSCLC and Response to Checkpoint Inhibitors2017immunology-2017abstractclinicalircnon-small-cell-lung-cancerpatient-response tumor-inflammation2017
Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification
Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification2017aacr-annual-meeting-2017abstractanalyticalircsolid-tumorsspecimen-characteristics validation2017
NGS reveals specimen characteristics have minimal impact on immune gene expression signature
NGS reveals specimen characteristics have minimal impact on immune gene expression signature2017aacr-annual-meeting-2017abstractanalyticaloirraspecimen-characteristics validation2017
Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient
Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient2017aacr-annual-meeting-2017abstractanalyticalircsolid-tumorsspecimen-characteristics validation2017
Analytical Validation of an Immune Response Assay for Classifying Solid Tumors
Analytical Validation of an Immune Response Assay for Classifying Solid Tumors20172017-asco-annual-meetingabstractanalyticalircanalytical-validation2017
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing2016oncotragetmanuscriptanalyticalircsolid-tumorscomparator-study specimen-characteristics validation2016
An Algorithmic Approach to Cancer Immune Profiling
An Algorithmic Approach to Cancer Immune Profiling2016sitcs-31st-annual-meeting-2016abstractanalyticalircsolid-tumorspatient-response predicitve-algorithm2016
Validation of a Custom RNA-Seq Approach to Cancer Immune Profiling
Validation of a Custom RNA-Seq Approach to Cancer Immune Profiling2016sitcs-31st-annual-meeting-2016abstractanalyticalircsolid-tumorscomparator-study specimen-characteristics validation2016